药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Rufinamide
The metabolism of Rufinamide can be decreased when combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Roflumilast
The metabolism of Roflumilast can be decreased when combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Inotersen
The risk or severity of QTc prolongation can be increased when Inotersen is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Pipemidic acid
The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Rufloxacin
The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Lidoflazine
The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Piromidic acid
The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Acetyldigoxin
The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Lorajmine
The risk or severity of QTc prolongation can be increased when Lorajmine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Oxolinic acid
The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Prajmaline
The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Bencyclane
The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Cibenzoline
The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Cicletanine
The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Givinostat
The risk or severity of QTc prolongation can be increased when Givinostat is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Temefos
The risk or severity of QTc prolongation can be increased when Temefos is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Tetrahydropalmatine
The risk or severity of QTc prolongation can be increased when Tetrahydropalmatine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Prulifloxacin
The risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
CUDC-907
The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Pazufloxacin
The risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Berotralstat.